Bio Pharma Dive
FEBRUARY 18, 2022
According to BioMarin, the regulator has requested additional data to assess the "theoretical" cancer risk to the treatment, information that will take "several quarters" to collect.
World of DTC Marketing
FEBRUARY 17, 2022
The mortality rate from lung cancer has dropped in recent decades—by 56% in men from 1990 to 2019 and by 32% in women from 2002 to 2019. In recent years, early detection and treatment improvements have helped boost the 3-year survival rate for lung cancer from 21% in 2004 to 31% in 2015 through 2017. The 5-year survival rate has increased by 6% for distant-stage lung cancer, 33% for a regional-stage disease, and 60% for localized disease.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Times
FEBRUARY 18, 2022
New combination treatment can significantly reduce the risk of death among prostate cancer patients
pharmaphorum
FEBRUARY 17, 2022
Akili Interactive’s prescription gaming app for attention deficit hyperactivity disorder (ADHD) EndeavorRx has been show to enhance neuronal activity in an area of the brain associated with attention function. The results come from a single-arm, unblinded study of the app, but add to the clinical evidence that EndeavorRx can have a positive impact on children with ADHD which led it to become the prescription game to be approved by the FDA in 2020.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Bio Pharma Dive
FEBRUARY 17, 2022
The layoffs — which, according to Yumanity, should be completed by April — are part of a larger restructuring effort meant to reduce costs after a recent setback to the company's most advanced drug program.
World of DTC Marketing
FEBRUARY 18, 2022
Business Insider formed a relationship with eMarketer for so-called “intelligence.” Their report on telehealth has numbers, but that’s not what’s important. We need to understand “why” people are using telehealth and for what purposes versus an in-office visit. In-office visits also have more benefits. Here is a quote from the report that is debatable at best “over the next few years, telehealth will remain the domain of the younger digital natives.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
pharmaphorum
FEBRUARY 18, 2022
The pandemic-induced transition to digital health is, according to the Nuffield Trust, contributing to an “inverse care law” that’s compounding existing health inequalities. But, as demonstrated by initiatives like the Telehealth Equity Coalition (TEC), the sector is taking a united stand against inequitable access. Technological solutions, from online clinics to app-based long-term condition management, have long been hailed as a solution to problems such as limited capacity and low patient aut
Bio Pharma Dive
FEBRUARY 15, 2022
Early study results suggest some efficacy for Amgen's KRAS-targeting drug in the tough-to-treat cancer type. The biotech plans to expand testing as a result.
World of DTC Marketing
FEBRUARY 15, 2022
Biotech startups are hurting for money as investments in biotech startups start to decline. Biotechs need to think like marketers to cut through the noise and attract investors. It begins with a CEO who not only has a stellar medical background but understands how to get the company on the radar. There are so many biotech startups right now that there isn’t enough money for them all to continue the development of new drugs.
Pharma Times
FEBRUARY 15, 2022
Oxford university spin out company develops tech to identify viruses in seconds
Pharma Mirror
FEBRUARY 18, 2022
Dean Kavanagh, Managing Director of QED Environmental Systems Ltd in the UK, has been appointed Co-Chair of the Council of Gas Detection and Environmental Monitoring (CoGDEM) Industry Subgroup. Dean will chair the Sub-group with Rob White, Sales Director of DD Scientific, with both chairs taking up their appointments early in 2022. The CoGDEM Industry Subgroup is one of the most influential steering groups, with meetings scheduled three times a year.
Bio Pharma Dive
FEBRUARY 16, 2022
Study results indicate the company's fast-acting medicine may help patients already on existing drugs. But its limited effects may curb its potential, Wall Street analysts said.
World of DTC Marketing
FEBRUARY 16, 2022
COVID may be winding down, but the damage is done in deaths and long COVID. We don’t understand much, but we do know that there is a correlation between COVID severity and obesity/diabetes. The question thus becomes, “will the medical community finally address the obesity epidemic, or will we continue to do nothing essentially?” Obesity turned out to be a significant risk factor for covid hospitalization and death, especially non-elderly.
Pharma Times
FEBRUARY 16, 2022
Saphnelo is the first therapy in over a decade for patients with moderate to severe systemic lupus erythematosus
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharma Mirror
FEBRUARY 18, 2022
By Christopher Weikart, Chief Scientist, SiO2 Materials Science Even though drugs are meant to save lives, the primary packaging used for delivering drug therapies and vaccines may actually be putting us in danger. The pharmaceutical industry works hard to create cutting-edge drugs to save lives and keep people healthy. From research to clinical trials, to go-to-market, drug makers are constantly seeking out new drug technologies and approaches to treat everyday illnesses and to end global pande
Bio Pharma Dive
FEBRUARY 14, 2022
At an industry conference Monday, a group of venture investors noted changes in how long biotechs are taking to raise money, and a shifting outlook among investors who specialize in shepherding young companies to an IPO.
Outsourcing Pharma
FEBRUARY 17, 2022
In its forward-looking report on digital health, the consulting outfit offers predictions on what changes are ahead and how they might impact the field.
Pharma Times
FEBRUARY 17, 2022
Vaccine pioneers expand presence throughout Europe with a view to leveraging technology
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Pharma Mirror
FEBRUARY 17, 2022
The importance of exosomes in skin cell regeneration has been extensively researched over the past few years. Functions involving the fibroblasts, forming of new blood vessels, and controlling the localized inflammatory response of the skin are all benefits of their use. Exosomes have another essential function, and that would be intercellular communication.
Bio Pharma Dive
FEBRUARY 16, 2022
Natalie Holles was named as head of the Atlas-backed startup last year after leaving gene therapy developer Audentes following its acquisition by Astellas.
JAMA Internal Medicine
FEBRUARY 17, 2022
This randomized clinical trial assesses the efficacy of ivermectin treatment in preventing progression to severe disease among high-risk patients with COVID-19 in Malaysia.
Pharma Times
FEBRUARY 14, 2022
UK health secretary navigates the NHS roadmap as he plans to reform the UK’s healthcare ecosystem
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharma Mirror
FEBRUARY 17, 2022
Although many labs are doing cutting-edge research and finding new ways to improve life in this world, they aren’t always the picture of productivity. Unfortunately, some labs are not very well organized internally and often could find ways to be more productive. Resources are often very limited so it makes sense to work on being more productive and wasting fewer resources to get the job done.
Bio Pharma Dive
FEBRUARY 14, 2022
The secret's in the biological context: how to accelerate biological discovery and validation.
pharmaphorum
FEBRUARY 18, 2022
Sanofi and Regeneron have reported disappointing results in a trial of Dupixent in people with chronic spontaneous urticaria (CSU) who don’t respond to the only approved biologic treatment, Novartis/Roche’s Xolair. . CSU is a severe form of hives that affects around 1% of the global population, causing severe itching and swelling that can last for weeks at a time and resist even very high doses of antihistamines, the standard, first-line therapy for the condition.
Pharma Times
FEBRUARY 18, 2022
Company focused on founding and building global leaders in life science sold to Novartis
Pharma Mirror
FEBRUARY 14, 2022
The concept of sustainability is gaining more traction in society with each passing day. Human activities pose numerous risks to the environment, so many industries and sectors are looking to become more sustainable. Can medical labs switch to greener practices without affecting the quality and accuracy of their output? The answer is a resounding yes.
Bio Pharma Dive
FEBRUARY 14, 2022
The European regulator began a safety review of so-called Janus kinase inhibitors from Pfizer, AbbVie, Eli Lilly and Galapagos, citing worrisome data from a study of Pfizer's drug Xeljanz.
pharmaphorum
FEBRUARY 15, 2022
One in four of the world’s rivers are polluted with potentially toxic levels of pharma compounds, according to a new study. The findings point to a “threat to environmental and global health,” say the scientists, who found that paracetamol, antibiotics epilepsy drug carbamazepine, metformin for diabetes and other compounds like caffeine and nicotine were found in samples from around the world – including in Antarctica.
Pharma Times
FEBRUARY 16, 2022
Rare Disease Day has inspired a pioneering video to support patients living with rare conditions
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Expert insights. Personalized for you.
344 
Let's personalize your content